Фибрилляция предсердий при гипертрофической кардиомиопатии: современные аспекты эпидемиологии, факторов риска, патогенеза и фармакотерапии

Обложка

Цитировать

Полный текст

Аннотация

Фибрилляция предсердий (ФП) - одно из основных нарушений ритма у пациентов с гипертрофической кардиомиопатией (ГКМП). В обзорной статье представлены данные об эпидемиологии, излагаются новейшие представления о факторах риска и патогенезе, в частности роли инсулинорезистентности в возникновении этого нарушения ритма при ГКМП. Отражены современные подходы к лечению данного нарушения ритма при ГКМП с учетом существующих международных рекомендаций.

Об авторах

Анна Алексеевна Стрельцова

ФГБУ «Национальный медицинский исследовательский центр им. В.А.Алмазова» Минздрава России

Email: anikas1985@gmail.com
врач ультразвуковой диагностики 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2

Александра Яковлевна Гудкова

ФГБУ «Национальный медицинский исследовательский центр им. В.А.Алмазова» Минздрава России ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России

Email: alexagood-1954@mail.ru
д-р мед. наук, зав. лаб. кардиомиопатий Института сердечно-сосудистых заболеваний, проф. каф. факультетской терапии 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2 ; 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8

Анна Александровна Костарева

ФГБУ «Национальный медицинский исследовательский центр им. В.А.Алмазова» Минздрава России ; ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П.Павлова» Минздрава России

Email: akostareva@hotmail.com
канд. мед. наук, доц. каф. факультетской терапии; дир. Института молекулярной биологии и генетики 197341, Россия, Санкт-Петербург, ул. Аккуратова, д. 2 ; 197022, Россия, Санкт-Петербург, ул. Льва Толстого, д. 6/8

Список литературы

  1. Authors/Task Force members, Elliott P.M, Anastasakis A, Borger M.A et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014; 35 (39): 2733-79. doi: 10.1093/eurheartj/ehu284
  2. Semsarian C, Ingles J, Maron M.S, Maron B.J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol 2015; 65 (12): 1249-54. doi: 10.1016/j.jacc.2015. 01.019
  3. Maron B.J, Maron M.S, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 2012; 60 (8): 705-15. doi: 10.1016/j.jacc.2012.02. 068
  4. Lopes L.R, Zekavati A, Syrris P et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. J Med Genet 2013; 50 (4): 228-39. doi: 10.1136/jmedgenet-2012-101270
  5. Kassem H.Sh, Azer R.S, Saber-Ayad M et al. Early results of sarcomeric gene screening from the Egyptian National BA-HCM Program. J Cardiovasc Translat Res 2013; 6 (1): 65-80. doi: 10.1007/s12265-012-9425-0
  6. Van Driest S.L, Ommen S.R, Tajik A.J et al. Yield of genetic testing in hypertrophic cardiomyopathy. Mayo Clinic Proceedings 2005; 80 (6): 739-44. doi: 10.4065/80.6.739
  7. Brito D, Miltenberger-Miltenyi G, Vale Pereira S et al. Sarcomeric hypertrophic cardiomyopathy: genetic profile in a Portuguese population. Rev Port Cardiol 2012; 31 (9): 577-87. doi: 10.1016/j.repc.2011.12.020
  8. Morita H, Rehm H.L, Menesses A et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358 (18): 1899-908. doi: 10.1056/NEJMoa075463
  9. Alfares A.A, Kelly M.A, McDermott G et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet Med 2015; 17 (11): 880-8. doi: 10.1038/gim.2014.205.
  10. Hodatsu A, Konno T, Hayashi K et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol - Heart and Circulatory Physiology 2014; 307 (11): H1594-H1604. doi: 10.1152/ajpheart.00637.2013
  11. Girolami F, Ho C.Y, Semsarian C et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010; 55 (14): 1444-53. doi: 10.1016/j.jacc.2009.11.062
  12. Li L, Bainbridge M.N, Tan Y et al. A potential oligogenic etiology of hypertrophic cardiomyopathy: a classic single-gene disorder. Circulation Res 2017; 120: 1084-90. doi: 10.1161/CIRCRESAHA.116.310559
  13. Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. doi: 10.1016/j.cjca.2017.07.007
  14. Marian A.J, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Res 2017; 121 (7): 749-70. doi: 10.1161/CIRCRESAHA.117.311059
  15. Eriksson M.J, Sonnenberg B, Woo A et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 39 (4): 638-45. doi: 10.1016/S0735-1097(01)01778-8
  16. Binder J, Attenhofer Jost C.H, Klarich K.W et al. Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. J Am Soc Echocardiogr 2011; 24 (7): 775-81. doi: 10.1016/j.echo.2011.03.002
  17. D’Amato R, Tomberli B, Castelli G et al. Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy. Am J Cardiol 2013; 112 (8): 1190-6. doi: 10.1016/j.amjcard.2013.06.018
  18. Guttmann O.P, Rahman M.S, O'Mahony C et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 2014; 100 (6): 465-72. doi: 10.1136/heartjnl-2013-304276
  19. Rowin E.J, Hausvater A, Link M. et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation 2017. doi: 10.1161/CIRCULATIONAHA.117.029267
  20. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm A.J, Kirchhof P, Lip G.Y et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369-29. doi: 10.1093/eurheartj/ehq278
  21. Lloyd-Jones D.M, Wang T.J, Leip E.P et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110 (9): 1042-6. doi: 10.1161/01.CIR. 0000140263.20897.42
  22. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38): 2893-962. doi: 10.1093/eurheartj/ehw210
  23. Camm C.F, Camm A.J. Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. Arrhythm and Electrophysiol Rev 2017; 6 (2): 63-8. doi: 10.15420/aer.2017.4.2
  24. Крылова Н.С., Демкина А.Е., Хашиева Ф.М. и др. Фибрилляция и трепетание предсердий у больных с гипертрофической кардиомиопатией. Рос. кардиол. журн. 2015; 5: 64-70. doi: 10.15829/1560-4071-2015-5-64-70.
  25. Gruver E.J, Fatkin D, Dodds G.A et al. Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 1999; 83 (12A): 13H-18H. doi: 10.1016/s0002-9149(99)00251-9
  26. Ogimoto A, Hamada M, Nakura J et al. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. J Hum Genet 2002; 47 (4): 184-9. doi: 10.1007/s100380200021
  27. Spirito P, Autore C, Formisano F et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol 2014; 113 (9): 1550-5. doi: 10.1016/j.amjcard.2014.01.435
  28. Tani T, Tanabe K, Ono M et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2004; 17 (6): 644-8. doi: 10.1016/j.echo.2004.02.010
  29. Olivotto I, Cecchi F, Casey S.A et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001; 104 (21): 2517-24. doi: 10.1161/hc4601.097997
  30. Losi M.A, Betocchi S, Aversa M et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004; 94 (1): 895-900. doi: 10.1016/j.amjcard.2004.06.024
  31. Siontis K.C, Geske J.B, Ong K et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Association 2014; 3 (3): e001002. doi: 10.1161/JAHA.114.001002
  32. Doesch C, Lossnitzer D, Rudic B et al. Right ventricular and right atrial involvement can predict atrial fibrillation in patients with hypertrophic cardiomyopathy? Int J Med Sci 2016; 13 (1): 1-7. doi: 10.7150/ijms.13530
  33. Autore C, Bernabo P, Barilla C.S et al. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45 (7): 1076-80. doi: 10.1016/j.jacc.2004.12.067
  34. Maron B.J, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102 (8): 858-64. doi: 10.1161/01.CIR.102.8.858
  35. Yang W.I, Shim C.Y, Kim Y.J et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009; 22 (12): 1338-43. doi: 10.1016/j.echo.2009.09.016
  36. Desai M.Y, Bhonsale A, Smedira N.G et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation 2013; 128 (3): 209-16. doi: 10.1161/CIRCULATIONAHA.112.000849
  37. Ohe T. Results from the Kochi RYOMA Study. Atrial fibrillation is a major risk of morbidity in patients with hypertrophic cardiomyopathy. Сirculation J 2009; 73 (9): 1589-90. doi: 10.1253/circj.CJ-09-0433
  38. Tian T, Wang Y, Sun K et al. Clinical profile and prognostic significance of atrial fibrillation in hypertrophic cardiomyopathy. Cardiology 2013; 126 (4): 258-64. doi: 10.1159/000354953
  39. Ash-Bernal R, Peterson L.R. The cardiometabolic syndrome and cardiovascular disease. J Cardiometabolic Syndrome. 2006; 1 (1): 25-8. doi: 10.1111/j.0197-3118.2006.05452.x
  40. Umetani K, Kodama Y, Nakamura T et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circulation J 2007; 71 (2): 252-5. doi: 10.1253/circj.71.252
  41. Watanabe H, Tanabe N, Watanabe T et al. Metabolic syndrome and risk of development of atrial fibrillation. The Niigata preventive medicine study. Circulation 2008; 117 (10): 1255-60. doi: 10.1161/CIRCULATIONAHA.107.744466
  42. ВНОК. Национальные рекомендации по диагностике и лечению метаболического синдрома. Кардиоваск. терапия и профилактика. 2007; 6 (6), Прил. 2.
  43. Баранова Е.И., Листопад О.В., Соболева А.В., Яцук Д.И. Гипертоническая болезнь и другие причины фибрилляции предсердий у пациентов, госпитализированных в терапевтическую клинику. Кардиология: новости, мнения, обучение. 2013; 1: 85-92.
  44. Nguyen J.T, Benditt D.G. Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 2008; 117 (10): 1249-51. doi: 10.1161/CIRCULATIONAHA.107.760777
  45. Russo C, Jin Z, Homma S et al. Effect of Obesity and Overweight on Left Ventricular Diastolic Function: a Community-based Study in an Elderly Cohort. J Am Col Cardiol 2011; 57 (12): 1368-74. doi: 10.1016/j.jacc.2010.10.042
  46. Ruige J.B, Assendelft W.J, Dekker J.M et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97 (10): 996-1001. doi: 10.1161/01.CIR.97.10.996
  47. Savage D.B, Petersen K.F, Shulman G.I. Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension 2005; 45 (5): 828-33. doi: 10.1161/01.HYP. 0000163475.04421.e4
  48. Chung M.K, Martin D.O, Sprecher D et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104 (24): 2886-91. doi: 10.1161/hc4901.101760
  49. Mihm M.J, Yu F, Carnes C.A et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104 (2): 174-80. doi: 10.1161/01.CIR.104.2.174
  50. Murakami K, Shigematsu Y, Hamada M, Higaki J. Insulin resistance in patients with hypertrophic cardiomyopathy. Circulation J 2004; 68 (7): 650-5. doi: 10.1253/circj.68.650
  51. Harano Y, Suzuki M, Koyama Y et al. Multifactorial insulin resistance and clinical impact in hypertension and cardiovascular diseases. J Diabetes Complications 2002; 16 (1): 19-23. doi: 10.1016/S1056-8727(01)00192-1
  52. Shigematsu Y, Hamada M, Nagai T et al. Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy: association with insulin resistance. J Cardiol 2011; 58 (1): 18-25. doi: 10.1016/j.jjcc.2011.03.001
  53. Gersh B.J, Maron B.J, Bonow R.O et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e783-831. doi: 10.1161/CIR.0b013e318223e2bd
  54. Cooper R.M, Raphael C.E, Liebregts M et al. New Developments in Hypertrophic Cardiomyopathy. Can J Cardiol 2017; 33 (10): 1254-65. doi: 10.1016/j.cjca.2017.07.007
  55. Moore J.C, Trager L, Anzia L.E et al. Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review. Pacing ClinElectrophysiol 2018. doi: 10.1111/pace.13310.
  56. Ammirati E, Contri R, Coppini R et al. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Failure 2016; 18 (9): 1106-18. doi: 10.1002/ejhf.541
  57. Quintana E, Cox J.L. Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothoracic Surg 2017; 6 (4): 386-93. doi: 10.21037/acs.2017.05.08.
  58. January C.T, Wann L.S, A.J.S Calkins H et al.; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130: e199-267. doi: 10.1161/CIR.0000000000000041
  59. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circulation J 2016; 80: 753-74. doi: 10.1253/circj.CJ-66-0122
  60. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013). Circulation J 2014; 78: 1997-2021. doi: 10.1253/circj.CJ-66-0092
  61. Лебедев Д.С., Михайлов Е.Н., Гуреев С.В. и др. Катетерная аблация хронической фибрилляции предсердий у пациента с гипертрофической кардиомиопатией. Вестн. аритмологии. 2008; 51: 72-4.
  62. Ikenaga H, Nakano Y, Oda N et al. Radiofrequency catheter ablation is effective for atrial fibrillation patients with hypertrophic cardiomyopathy by decreasing left atrial pressure. J Arrhythmia 2017; 33 (4): 256-61. doi: 10.1016/j.joa.2016.08.006
  63. Providencia R, Elliott P, Patel K et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart (British Cardiac Society) 2016; 102 (19): 1533-43. doi: 10.1136/heartjnl-2016-309406
  64. Maagh P, Plehn G, Christoph A et al. Impact of Cryoballoon Ablation in Hypertrophic Cardiomyopathy-related Heart Failure due to Paroxysmal Atrial Fibrillation. A Comparative Case Series. Int J Med Sci 2016; 13 (9): 664-72. doi: 10.7150/ijms.16181
  65. Бокерия Л.А., Бокерия О.Л., Климчук И.Я., Санакоев М.К. Хирургическая коррекция обструктивной гипертрофической кардиомиопатии с SAM-синдромом и фибрилляцией предсердий. Анналы аритмологии. 2016; 13 (4): 216-21. doi: 10.15275/annaritmol.2016.4.4

© ООО "Консилиум Медикум", 2018

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах